IP Library › Granted Patent US 12,377,116
Granted Patent B2
US 12,377,116 · App. 17/631,704 · Granted Aug 5, 2025

Composition for enhancing effect of antibody drug

Inventors: Ko Rii (Tokyo, JP); Masayuki Fujino (Tokyo, JP); Yukiko Moriya (Kimitsu, JP)
Assignees: AUREO CO., LTD.; NATIONAL CENTER HEALTH AND DEVELOPMENT
A61K31/716A61P35/00C07K16/2827
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,116
App. No.
17/631,704
Granted
Aug 5, 2025
Kind
B2
Abstract

Provided is a composition capable of enhancing the effect of an antibody drug such as an immune checkpoint inhibitor, etc. A β-glucan is used as an active ingredient of a composition for enhancing the effect of an antibody drug. This composition is used suitably for antibody drugs that have an effect of suppressing growth of cancer via immune checkpoint inhibition; e.g., antibody drugs including a monoclonal antibody to PD-L1.

Claims (4)

1. A method for enhancing the effect of an antibody drug, the method comprising:

administrating a composition containing a β-glucan as an active ingredient together with the antibody drug to a melanoma patient in need thereof,

wherein the β-glucan is derived from Aureobasidium pullulans;

wherein the antibody drug suppresses growth of melanoma via immune checkpoint inhibition, wherein said administering provides a synergistic suppressive effect on the growth of melanoma, and the antibody drug is a monoclonal antibody to PD-L1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: RII, KO; FUJINO, MASAYUKI; MORIYA, YUKIKO
To: AUREO CO., LTD.; NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT
Reel/Frame 058850/0331 →
Priority Claims (1)
JP 2019-165722 · Sep 11, 2019 · national
Continuity (1)
Related Publication 20220265698A1 · Aug 25, 2022
References Cited (38)
US 8802433B2 · Moriya et al. · 2014 [cited by applicant]
US 10111901B2 · Bose et al. · 2018 [cited by applicant]
US 20080293669A1 · Moriya et al. · 2008 [cited by applicant]
US 20100068184A1 · Moriya et al. · 2010 [cited by applicant]
US 20120202771A1 · Moriya et al. · 2012 [cited by applicant]
US 20150297651A1 · Moriya et al. · 2015 [cited by applicant]
US 20170100424A1 · Bose · 2017 [cited by examiner]
JP 2002204687A · 2002 [cited by applicant]
JP 4000078B2 · 2007 [cited by applicant]
JP 4054697B2 · 2008 [cited by applicant]
JP 4369258B2 · 2009 [cited by applicant]
JP 5242855B2 · 2013 [cited by applicant]
JP 5331482B2 · 2013 [cited by applicant]
JP 5554221B2 · 2014 [cited by applicant]
JP 5559173B2 · 2014 [cited by applicant]
JP 5560472B2 · 2014 [cited by applicant]
JP 5715659B2 · 2015 [cited by applicant]
JP 5937029B2 · 2016 [cited by applicant]
JP 2017524737A · 2017 [cited by applicant]
JP 6293187B2 · 2018 [cited by applicant]
JP 6380968B2 · 2018 [cited by applicant]
WO 2006027914A1 · 2006 [cited by applicant]
WO 2016007876A1 · 2016 [cited by applicant]
WO 2016073763A2 · 2016 [cited by applicant]
WO 2017120604A1 · 2017 [cited by applicant]
Liu et al., Combined yeast-derived β-glucan with anti-tumor monoclonal antibody for cancer immunotherapy, 2009, Experimental and Molecular Pathology, 86, 208-214. (Year: 2009). [cited by examiner]
Extended European Search Report issued Sep. 19, 2023 in European Application No. 20862447.8. [cited by applicant]
Office Action dated Sep. 22, 2023 issued in corresponding CN patent application No. 202080061449.2. [cited by applicant]
English Translation of International Preliminary Report on Patentability dated Mar. 17, 2022 in International Application No. PCT/JP2020/034361. [cited by applicant]
Yasumasa Ishida, et al., “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death”, The EMBO Journal, 1992, pp. 3887-3895, vol. 11, No. 11. [cited by applicant]
Gordon J. Freeman, et al., “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation”, J. Exp. Med., Oct. 2, 2000, vol. 192, No. 7. [cited by applicant]
Spencer C. Wei, et al., “Fundamental Mechanisms of Immune Checkpoint Blockade Therapy”, Cancer Discovery, Sep. 2018, pp. 1069-1086. [cited by applicant]
Curtis A. Clark, et al., “Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma”, Cancer Research, Dec. 1, 2016, pp. 6964-6974, vol. 76, No. 23. [cited by applicant]
Yoshiyuki Kimura, et al., “Antitumor and antimetastatic effects of β-glucan in clolon 26-implanted mice” Proceedings of the Japanese Cancer Association, 2004, p. 456, vol. 63, P-1197. [cited by applicant]
Kaori Yamasaki, et al., “Antitumor effect by oral administration of extracellular β-glucan of black yeast”, Lecture abstracts of the Annual Meeting of the Japan Society of Bioscience, Biotechnology, and Agrochemistry, M… [cited by applicant]
International Search Report for PCT/JP2020/034361 dated Oct. 27, 2020 [PCT/ISA/210]. [cited by applicant]
Written Opinion for PCT/JP2020/034361 dated Oct. 27, 2020 [PCT/ISA/237]. [cited by applicant]
International Preliminary Report on Patentability for PCT/JP2020/034361 dated Oct. 19, 2020 [PCT/IPEA/409]. [cited by applicant]